Enovix Corporation ENVX · NASDAQ
$2.51 -3.09% (-$0.08)
Summary
25 / 100 · Bulios Score
What speaks for it
- Revenue grew by 72% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- It bought back its own shares for $58.4M in the last fiscal year, 11% of its market value.
What to watch
- The company made a loss over the last 12 months.
- It passes only 3 of the 9 points of the Piotroski financial health test.
- Analysts expect revenue to fall by 4.0% this fiscal year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapPrice against the Bulios Fair Price
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 72% a year over the last 3 years. For the next fiscal year analysts expect revenue to fall by 4.0%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $170.0M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 13
- Hold 4
- Sell 1
Today's price within the analysts' price targets
The average target of $10.75 is 328% above today's price. 72% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 100%
By region
- Asia Pacific 68%
- SWITZERLAND 14%
- UNITED STATES 6.7%
- NORWAY 4.8%
- Other 3.7%
- Other 3.2%
Product brings in 100% of revenue.
Segments in detail